Ming Ren
Ming Ren has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
Jianguo Liu
Department of Neurology, The First Medical Center, Chinese PLA General Hospital, Beijing, China
2 shared publicationsXunming Ji
Department of Neurology, Beijing Xuanwu Hospital, Beijing, People's Republic of China
2 shared publications- Yingxin Yu
Department of Neurology, The First Medical Center, Chinese PLA General Hospital, Beijing, China
2 shared publications Zhiwei Wang
Department of Neurology, The First Medical Center, Chinese PLA General Hospital, Beijing, China
2 shared publicationsBaolei Xu
National Clinical Research Center for Geriatric Diseases, Xuanwu Hospital, Capital Medical University, Beijing, China
1 shared publicationBixiu Yang
Department of Psychology, Wuxi Mental Health Center, Wuxi, China
1 shared publication
Latest Publications
- Open Access
- 17 November 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (1) , 286-302
Global, regional, and national burden of brain and other central nervous system cancers from 1990 to 2021, and projections to 2035: a systematic analysis for the global burden of disease study 2021
Background: The burden of primary brain and other central nervous system (CNS) cancers, collectively termed CNS cancers, has undergone significant changes in recent decades. This study aimed to estimate the burden, trends, and inequalities at the global, regional, and national levels from 1990 to 2021, as well as projections to 2035. Methods: We used 2021 Global Burden of Disease (GBD) Study data and methodologies to describe changes in the burden of CNS cancers from 1990 to 2021, including prevalence, incidence, mortality, and disability-adjusted life years (DALYs). Furthermore, the autoregressive integrated moving average model was used to forecast the future CNS cancer burden until 2035. Finally, we conducted decomposition analysis to identify the key drivers of variation in CNS cancer burden. Frontier analysis was used to visually illustrate the potential for burden reduction in each country or region based on their development levels. Results: From 1990 to 2021, global cases of CNS cancers have increased in prevalence and incidence by 124.50% and 106.53%, respectively, with corresponding increases in related age-standardized rates (ASRs). A similar increase in the number was also observed in CNS cancer-related mortality and DALYs, accompanied by a decline in the ASRs of DALYs and a stable state in the ASRs of mortality. Sex and age data from the GBD 2021 demonstrated an exclusively older male predominance in CNS cancer-related ASRs of prevalence, incidence, mortality, and DALYs. In 2021, regions with a high Socio-Demographic Index (SDI) had the highest ASRs of prevalence, incidence, mortality, and DALYs. By 2035, the estimated global number of prevalent cases, incident cases, deaths, and DALYs is projected to be 1.22 million, 0.43 million, 0.31 million, and 10.27 million, with an increase of 24%, 19%, 19%, and 15% from 2021 to 2035, respectively, though the ASRs of incidence and DALYs decreased to some extent. Decomposition analysis showed the major contributory roles of population growth and aging on the incidence, mortality, and DALYs, although epidemiological changes also contributed to the prevalence to some extent. Frontier analysis of 204 countries and regions indicated that a higher SDI was associated with higher CNS cancer-related ASRs of prevalence, incidence, mortality, and DALYs and that countries or regions with higher SDI levels tended to have greater potential for improvement. Conclusions: Life expectancy for individuals with CNS cancers has increased since the 1990s, coinciding with a substantial reduction in the DALY rate and a stable CNS cancer-related mortality rate. However, mortality and DALYs related to CNS cancers have been particularly high in men across all age groups, those residing in higher SDI regions, and older adults. Considering the continuous increase in the CNS cancer burden by 2035, efficacious management of CNS cancers continues to pose a substantial challenge, highlighting the need for more regionally tailored strategies and guidelines on the sex-specific treatment protocols for older males to alleviate the disease burden, which is largely driven by aging and population growth in different SDI regions.
- 17 November 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (1) , 286-302
Open AccessGlobal, regional, and national burden of brain and other central nervous system cancers from 1990 to 2021, and projections to 2035: a systematic analysis for the global burden of disease study 2021
Background: The burden of primary brain and other central nervous system (CNS) cancers, collectively termed CNS cancers, has undergone significant changes in recent decades. This study aimed to estimate the burden, trends, and inequalities at the global, regional, and national levels from 1990 to 2021, as well as projections to 2035. Methods: We used 2021 Global Burden of Disease (GBD) Study data and methodologies to describe changes in the burden of CNS cancers from 1990 to 2021, including prevalence, incidence, mortality, and disability-adjusted life years (DALYs). Furthermore, the autoregressive integrated moving average model was used to forecast the future CNS cancer burden until 2035. Finally, we conducted decomposition analysis to identify the key drivers of variation in CNS cancer burden. Frontier analysis was used to visually illustrate the potential for burden reduction in each country or region based on their development levels. Results: From 1990 to 2021, global cases of CNS cancers have increased in prevalence and incidence by 124.50% and 106.53%, respectively, with corresponding increases in related age-standardized rates (ASRs). A similar increase in the number was also observed in CNS cancer-related mortality and DALYs, accompanied by a decline in the ASRs of DALYs and a stable state in the ASRs of mortality. Sex and age data from the GBD 2021 demonstrated an exclusively older male predominance in CNS cancer-related ASRs of prevalence, incidence, mortality, and DALYs. In 2021, regions with a high Socio-Demographic Index (SDI) had the highest ASRs of prevalence, incidence, mortality, and DALYs. By 2035, the estimated global number of prevalent cases, incident cases, deaths, and DALYs is projected to be 1.22 million, 0.43 million, 0.31 million, and 10.27 million, with an increase of 24%, 19%, 19%, and 15% from 2021 to 2035, respectively, though the ASRs of incidence and DALYs decreased to some extent. Decomposition analysis showed the major contributory roles of population growth and aging on the incidence, mortality, and DALYs, although epidemiological changes also contributed to the prevalence to some extent. Frontier analysis of 204 countries and regions indicated that a higher SDI was associated with higher CNS cancer-related ASRs of prevalence, incidence, mortality, and DALYs and that countries or regions with higher SDI levels tended to have greater potential for improvement. Conclusions: Life expectancy for individuals with CNS cancers has increased since the 1990s, coinciding with a substantial reduction in the DALY rate and a stable CNS cancer-related mortality rate. However, mortality and DALYs related to CNS cancers have been particularly high in men across all age groups, those residing in higher SDI regions, and older adults. Considering the continuous increase in the CNS cancer burden by 2035, efficacious management of CNS cancers continues to pose a substantial challenge, highlighting the need for more regionally tailored strategies and guidelines on the sex-specific treatment protocols for older males to alleviate the disease burden, which is largely driven by aging and population growth in different SDI regions.
- Open Access
- 1 March 2025
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 21, 611-619
A Pilot Study of Remote Ischemic Conditioning in Preventing Post-Stroke Depression
Post-stroke depression (PSD) constitutes a significant complication that influences both patient survival and functional recovery following a stroke. Despite its prevalence, PSD still lacks a long-term, safe and effective treatment measure. Remote ischemic conditioning (RIC) is a simple and noninvasive procedure that exert neuroprotective effects. This pilot study aims to investigate the efficacy, safety, and feasibility of RIC as a preventive measure against PSD. Acute ischemic stroke patients within 15 days post-event were considered eligible for study enrollment. Fifty participants were recruited and underwent daily RIC treatments for a 12-month period. Depressive symptoms were assessed utilizing the Patient Health Questionnaire-9 (PHQ-9) and the Hamilton Depression Rating Scale (HAMD) at baseline, as well as at 1, 3, 6, and 12-months post-intervention. The study found a gradual improvement in depressive symptoms among the 50 patients who completed the study over the 12-month treatment period, as evidenced by a consistent decline in pertinent scores. Moreover, merely two patients experienced mild adverse reactions. The study's outcomes indicate that RIC is safe, well-tolerated, and feasible as a preventive measure for PSD. Consequently, it is advisable to conduct a comprehensive randomized controlled trial to further evaluate the effectiveness and safety of RIC in preventing PSD.
- 1 March 2025
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 21, 611-619
Open AccessA Pilot Study of Remote Ischemic Conditioning in Preventing Post-Stroke Depression
Post-stroke depression (PSD) constitutes a significant complication that influences both patient survival and functional recovery following a stroke. Despite its prevalence, PSD still lacks a long-term, safe and effective treatment measure. Remote ischemic conditioning (RIC) is a simple and noninvasive procedure that exert neuroprotective effects. This pilot study aims to investigate the efficacy, safety, and feasibility of RIC as a preventive measure against PSD. Acute ischemic stroke patients within 15 days post-event were considered eligible for study enrollment. Fifty participants were recruited and underwent daily RIC treatments for a 12-month period. Depressive symptoms were assessed utilizing the Patient Health Questionnaire-9 (PHQ-9) and the Hamilton Depression Rating Scale (HAMD) at baseline, as well as at 1, 3, 6, and 12-months post-intervention. The study found a gradual improvement in depressive symptoms among the 50 patients who completed the study over the 12-month treatment period, as evidenced by a consistent decline in pertinent scores. Moreover, merely two patients experienced mild adverse reactions. The study's outcomes indicate that RIC is safe, well-tolerated, and feasible as a preventive measure for PSD. Consequently, it is advisable to conduct a comprehensive randomized controlled trial to further evaluate the effectiveness and safety of RIC in preventing PSD.
- Open Access
- 22 January 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1519700
Autoimmune glial fibrillary acidic protein astrocytopathy misdiagnosed as intracranial infectious diseases: case reports and literature review
Background: Autoimmune glial fibrillary acidic protein astrocytopathy (A-GFAP-A) is an autoimmune central nervous system(CNS) disease characterized by GFAP IgG as a biomarker. Several cases of individuals with A-GFAP-A initially misdiagnosed as infectious diseases of the central nervous system have been reported in research. We report three cases of A-GFAP-A misdiagnosed as viral meningitis or tuberculous meningitis (TBM). We summarize recent cases of A-GFAP-A misdiagnosed as central nervous system infections through a literature review.Materials and methods: Three cases of A-GFAP-A were initially misdiagnosed as tuberculous or viral meningitis. Their diagnoses of A-GFAP-A were confirmed with positive GFAP-IgG in cerebrospinal fluid (CSF). We searched the PubMed database with the key words of “GFAP astrocytopathy”, “GFAP autoimmunity”, “GFAP autoantibody”, “intracranial infection”, “meningitis”, “misdiagnose”, and within the literature from Jan 1, 2015 to Mar 15, 2024, 40 cases with A-GFAP-A with positive GFAP-IgG in CSF who were previously misdiagnosed with intracranial infection were reported. The causes of misdiagnoses were summarized and analyzed.Results: Case 1 was a 41-year-old female, presenting with headache, fever, diplopia, and altered consciousness level. Anti-tuberculosis treatment was ineffective. Finally, with positive GFAP IgG in CSF, she was diagnosed with A-GFAP-A. Case 2 was a 74-year-old male, presenting with fever, excessive sweating, fatigue, and memory loss. Anti-tuberculosis treatment was ineffective. With positive GFAP IgG in CSF, he was diagnosed with A-GFAP-A. Case 3 was a 54-year-old male, presenting with fever, personality changes, and memory decline. Antiviral treatment was ineffective. His diagnosis was revised to A-GFAP-A after testing positive for GFAP IgG in CSF. Our study summarized a total of 40 patients with A-GFAP-A who were initially misdiagnosed as intracranial infections. The most common clinical phenotypes among 40 patients were mimicked meningitis, meningoencephalitis, meningoencephalomyelitis, encephalitis and encephalomyelitis.Conclusion: A-GFAP-A is a specific autoimmune meningoencephalomyelitis associated with GFAP-IgG, with lesions involved the brain, meninges, and spinal cord. It commonly presents with symptoms such as fever, headache, altered consciousness, tremor, seizures, and autonomic dysfunction. Brain MRI often shows characteristic linear perivascular radial enhancement perpendicular to the ventricles or nonspecific leptomeningeal enhancement. Early detection of GFAP-IgG in serum and CSF is essential for differential diagnosis.
- 22 January 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1519700
Open AccessAutoimmune glial fibrillary acidic protein astrocytopathy misdiagnosed as intracranial infectious diseases: case reports and literature review
Background: Autoimmune glial fibrillary acidic protein astrocytopathy (A-GFAP-A) is an autoimmune central nervous system(CNS) disease characterized by GFAP IgG as a biomarker. Several cases of individuals with A-GFAP-A initially misdiagnosed as infectious diseases of the central nervous system have been reported in research. We report three cases of A-GFAP-A misdiagnosed as viral meningitis or tuberculous meningitis (TBM). We summarize recent cases of A-GFAP-A misdiagnosed as central nervous system infections through a literature review.Materials and methods: Three cases of A-GFAP-A were initially misdiagnosed as tuberculous or viral meningitis. Their diagnoses of A-GFAP-A were confirmed with positive GFAP-IgG in cerebrospinal fluid (CSF). We searched the PubMed database with the key words of “GFAP astrocytopathy”, “GFAP autoimmunity”, “GFAP autoantibody”, “intracranial infection”, “meningitis”, “misdiagnose”, and within the literature from Jan 1, 2015 to Mar 15, 2024, 40 cases with A-GFAP-A with positive GFAP-IgG in CSF who were previously misdiagnosed with intracranial infection were reported. The causes of misdiagnoses were summarized and analyzed.Results: Case 1 was a 41-year-old female, presenting with headache, fever, diplopia, and altered consciousness level. Anti-tuberculosis treatment was ineffective. Finally, with positive GFAP IgG in CSF, she was diagnosed with A-GFAP-A. Case 2 was a 74-year-old male, presenting with fever, excessive sweating, fatigue, and memory loss. Anti-tuberculosis treatment was ineffective. With positive GFAP IgG in CSF, he was diagnosed with A-GFAP-A. Case 3 was a 54-year-old male, presenting with fever, personality changes, and memory decline. Antiviral treatment was ineffective. His diagnosis was revised to A-GFAP-A after testing positive for GFAP IgG in CSF. Our study summarized a total of 40 patients with A-GFAP-A who were initially misdiagnosed as intracranial infections. The most common clinical phenotypes among 40 patients were mimicked meningitis, meningoencephalitis, meningoencephalomyelitis, encephalitis and encephalomyelitis.Conclusion: A-GFAP-A is a specific autoimmune meningoencephalomyelitis associated with GFAP-IgG, with lesions involved the brain, meninges, and spinal cord. It commonly presents with symptoms such as fever, headache, altered consciousness, tremor, seizures, and autonomic dysfunction. Brain MRI often shows characteristic linear perivascular radial enhancement perpendicular to the ventricles or nonspecific leptomeningeal enhancement. Early detection of GFAP-IgG in serum and CSF is essential for differential diagnosis.
- Open Access
- 21 October 2021
- Published by Wiley in Brain and Behavior
- Vol. 11 (11) , e32365
Anti‐PrP monoclonal antibody as a novel treatment for neurogenesis in mouse model of Alzheimer's disease
Background: Alzheimer's disease (AD) is the most common degenerative disease characterized by cognitive impairment, memory decline, and language disorder for which there is no effective treatment. Neurogenesis has been indicated in AD and may play an important role in the pathogenesis of AD. Targeting this pathway is a new idea for the treatment of the disease. A recent study reveals that the cellular prion protein (PrP), a receptor for Aβ oligomers, regulates neurogenesis, and its elevated expression is related to cell differentiation. The aim of the present study was to investigate the neuroprotective effects of 6D11 (PrP monoclonal antibody) via neurogenesis promotion in APP/PS1 transgenic mice and Aβ‐induced cell model of AD.Methods: In the present study, 9‐month‐old male APP/PS1 mice were injected with 6D11. Then, the Morris water maze was used to examine the spatial learning and memory abilities of the mice in both groups, and immunostained was used to assess the level of Aβ, neurogenesis, and neural stem cells (NSCs) differentiation.Results: 6D11 attenuated cognitive deficits in APP/PS1 transgenic mice, which was accompanied by a decrease of the deposition of Aβ. In addition, 6D11 treatment promoted differentiation of the existing hippocampal cells to neurons.Conclusions: Our findings confirmed that 6D11 has a therapeutic effect in APP/PS1 transgenic AD mouse model and Aβ‐induced AD cell model, and the effect exerted via increase of neurogenesis and cell differentiation by transduction of Aβ peptide signal.
- 21 October 2021
- Published by Wiley in Brain and Behavior
- Vol. 11 (11) , e32365
Open AccessAnti‐PrP monoclonal antibody as a novel treatment for neurogenesis in mouse model of Alzheimer's disease
Background: Alzheimer's disease (AD) is the most common degenerative disease characterized by cognitive impairment, memory decline, and language disorder for which there is no effective treatment. Neurogenesis has been indicated in AD and may play an important role in the pathogenesis of AD. Targeting this pathway is a new idea for the treatment of the disease. A recent study reveals that the cellular prion protein (PrP), a receptor for Aβ oligomers, regulates neurogenesis, and its elevated expression is related to cell differentiation. The aim of the present study was to investigate the neuroprotective effects of 6D11 (PrP monoclonal antibody) via neurogenesis promotion in APP/PS1 transgenic mice and Aβ‐induced cell model of AD.Methods: In the present study, 9‐month‐old male APP/PS1 mice were injected with 6D11. Then, the Morris water maze was used to examine the spatial learning and memory abilities of the mice in both groups, and immunostained was used to assess the level of Aβ, neurogenesis, and neural stem cells (NSCs) differentiation.Results: 6D11 attenuated cognitive deficits in APP/PS1 transgenic mice, which was accompanied by a decrease of the deposition of Aβ. In addition, 6D11 treatment promoted differentiation of the existing hippocampal cells to neurons.Conclusions: Our findings confirmed that 6D11 has a therapeutic effect in APP/PS1 transgenic AD mouse model and Aβ‐induced AD cell model, and the effect exerted via increase of neurogenesis and cell differentiation by transduction of Aβ peptide signal.
- Open Access
- 18 June 2020
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 11, 570
Safety and Tolerability of Both Arm Ischemic Conditioning in Patients With Major Depression: A Proof of Concept Study
Purpose: A substantial proportion of patients with major depressive disorder (MDD) does not respond or cannot tolerate to currently available treatments. This study was to assess the safety and tolerability of Remote Limb Ischemic Preconditioning (RLIPC) as an adjunctive therapy in patients with MDD. Patients and Methods: Enrolled patients underwent RLIPC, five cycles of simultaneous bilateral arm ischemia, 5 min and followed by reperfusion of each cycle, and once daily for eight consecutive weeks. Depression and anxiety severity, and quality of life were assessed every 2 weeks. Descriptive analysis was used for safety and tolerability data. Results: Thirty-seven participants completed at least one RLIPC. Twenty-four of them (64.9%) completed the study. Twelve patients prematurely discontinued the study due to poor adherence, and one due to a mild side effect. The changes in HRSD-17, GAD-7 and QOL-6 total scores from baseline to the endpoint were significant from the end of second week treatment onwards. The responder and remission rates were 59.46% (22/37) and 54.05% (20/37) at the endpoint, respectively. Conclusion: RLIPC was safe and well tolerated, and may be effective in reducing depressive symptoms in patients with MDD. Large studies are warranted to test its efficacy and safety as monotherapy or adjunctive therapy in the treatment of MDD.
- 18 June 2020
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 11, 570
Open AccessSafety and Tolerability of Both Arm Ischemic Conditioning in Patients With Major Depression: A Proof of Concept Study
Purpose: A substantial proportion of patients with major depressive disorder (MDD) does not respond or cannot tolerate to currently available treatments. This study was to assess the safety and tolerability of Remote Limb Ischemic Preconditioning (RLIPC) as an adjunctive therapy in patients with MDD. Patients and Methods: Enrolled patients underwent RLIPC, five cycles of simultaneous bilateral arm ischemia, 5 min and followed by reperfusion of each cycle, and once daily for eight consecutive weeks. Depression and anxiety severity, and quality of life were assessed every 2 weeks. Descriptive analysis was used for safety and tolerability data. Results: Thirty-seven participants completed at least one RLIPC. Twenty-four of them (64.9%) completed the study. Twelve patients prematurely discontinued the study due to poor adherence, and one due to a mild side effect. The changes in HRSD-17, GAD-7 and QOL-6 total scores from baseline to the endpoint were significant from the end of second week treatment onwards. The responder and remission rates were 59.46% (22/37) and 54.05% (20/37) at the endpoint, respectively. Conclusion: RLIPC was safe and well tolerated, and may be effective in reducing depressive symptoms in patients with MDD. Large studies are warranted to test its efficacy and safety as monotherapy or adjunctive therapy in the treatment of MDD.
- Open Access
- 1 November 2019
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 15, 3061-3067
Differential Diagnosis Of Multiple-System Atrophy With Parkinson’s Disease By External Anal- And Urethral-Sphincter Electromyography
Background: The differential diagnosis of Parkinson’s disease (PD) with multiple-system atrophy (MSA) is difficult because of their similarity in symptoms and signs. The objective of this study was to investigate the value of external anal-sphincter electromyography (EAS-EMG) and urethral-sphincter electromyography (US-EMG) in differentiating MSA from PD. Methods: A total of 201 patients, — 101 MSA and 100 PD — were recruited in this study. Average duration and amplitude of motor unit potentials (MUPs), percentage of polyphasic MUPs, amplitude during strong contractions, and recruitment patterns during maximal voluntary contractions were recorded and analyzed to assess diagnostic efficiency of EAS-EMG and US-EMG for MSA. Results: Significant differences in average MUP duration and recruitment patterns during maximal voluntary contractions were found between patients with MSA and patients with PD using both EAS-EMG (PPPPPP=0.005). Cutoff points for average MUP duration in EAS-EMG and US-EMG for differential diagnosis of MSA with PD were 10.9 and 11.1 milliseconds, respectively. With average MUP duration of EAS-EMG and US-EMG being applied jointly, sensitivity and specificity in distinguishing MSA from PD were 83.2% and 71.8%, respectively. Conclusion: EAS-EMG and US-EMG were sensitive and specific methods for the diagnosis and differential diagnosis of MSA, and the combination of both would improve the diagnostic rate of MSA compared to only one method being used.
- 1 November 2019
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 15, 3061-3067
Open AccessDifferential Diagnosis Of Multiple-System Atrophy With Parkinson’s Disease By External Anal- And Urethral-Sphincter Electromyography
Background: The differential diagnosis of Parkinson’s disease (PD) with multiple-system atrophy (MSA) is difficult because of their similarity in symptoms and signs. The objective of this study was to investigate the value of external anal-sphincter electromyography (EAS-EMG) and urethral-sphincter electromyography (US-EMG) in differentiating MSA from PD. Methods: A total of 201 patients, — 101 MSA and 100 PD — were recruited in this study. Average duration and amplitude of motor unit potentials (MUPs), percentage of polyphasic MUPs, amplitude during strong contractions, and recruitment patterns during maximal voluntary contractions were recorded and analyzed to assess diagnostic efficiency of EAS-EMG and US-EMG for MSA. Results: Significant differences in average MUP duration and recruitment patterns during maximal voluntary contractions were found between patients with MSA and patients with PD using both EAS-EMG (PPPPPP=0.005). Cutoff points for average MUP duration in EAS-EMG and US-EMG for differential diagnosis of MSA with PD were 10.9 and 11.1 milliseconds, respectively. With average MUP duration of EAS-EMG and US-EMG being applied jointly, sensitivity and specificity in distinguishing MSA from PD were 83.2% and 71.8%, respectively. Conclusion: EAS-EMG and US-EMG were sensitive and specific methods for the diagnosis and differential diagnosis of MSA, and the combination of both would improve the diagnostic rate of MSA compared to only one method being used.
- Open Access
- 20 October 2015
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 7, 204
PGC-1α Silencing Compounds the Perturbation of Mitochondrial Function Caused by Mutant SOD1 in Skeletal Muscle of ALS Mouse Model
Amyotrophic lateral sclerosis (ALS) is a lethal neurodegenerative disease causing death of motor neurons. This study investigated the roles of energy metabolism in the pathogenesis of ALS in the SOD1(G93A) transgenic mouse model. Control and SOD1(G93A) mice were administered with shcontrol or shPGC-1α in combination with PBS or TZD for 8 weeks. Gene expression was analyzed by quantitative real-time PCR and western blot. ROS and fibrosis were assessed with a colorimetric kit and Sirius staining respectively. Inflammatory cytokines were measured using ELISA kits. The levels of tissue ROS and serum inflammatory cytokines were significantly higher in SOD1(G93A) mice compared to control mice, and knocking down PGC-1α drastically increased cytokine levels in both control and SOD1(G93A) mice. Muscle fibrosis was much severer in SOD1(G93A) mice, and worsened by silencing PGC-1α and attenuate d by TZD. The expression levels of PGC-1α, SOD1, UCP2, and cytochrome C were substantially reduced by shPGC-1α and increased by TZD in muscle of both control and SOD1(G93A) mice whereas the level of NF-B was significantly elevated in SOD1(G93A) mice, which was further increased by PGC-1α silencing. These data indicated that disruption of energy homeostasis would exacerbate the pathological changes caused by SOD1 mutations to promote the pathogenesis of ALS.
- 20 October 2015
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 7, 204
Open AccessPGC-1α Silencing Compounds the Perturbation of Mitochondrial Function Caused by Mutant SOD1 in Skeletal Muscle of ALS Mouse Model
Amyotrophic lateral sclerosis (ALS) is a lethal neurodegenerative disease causing death of motor neurons. This study investigated the roles of energy metabolism in the pathogenesis of ALS in the SOD1(G93A) transgenic mouse model. Control and SOD1(G93A) mice were administered with shcontrol or shPGC-1α in combination with PBS or TZD for 8 weeks. Gene expression was analyzed by quantitative real-time PCR and western blot. ROS and fibrosis were assessed with a colorimetric kit and Sirius staining respectively. Inflammatory cytokines were measured using ELISA kits. The levels of tissue ROS and serum inflammatory cytokines were significantly higher in SOD1(G93A) mice compared to control mice, and knocking down PGC-1α drastically increased cytokine levels in both control and SOD1(G93A) mice. Muscle fibrosis was much severer in SOD1(G93A) mice, and worsened by silencing PGC-1α and attenuate d by TZD. The expression levels of PGC-1α, SOD1, UCP2, and cytochrome C were substantially reduced by shPGC-1α and increased by TZD in muscle of both control and SOD1(G93A) mice whereas the level of NF-B was significantly elevated in SOD1(G93A) mice, which was further increased by PGC-1α silencing. These data indicated that disruption of energy homeostasis would exacerbate the pathological changes caused by SOD1 mutations to promote the pathogenesis of ALS.